Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Hirsutenone is a naturally occurring diarylheptanoid compound primarily isolated from the bark and leaves of Alnus species, such as Alnus japonica and Alnus nepalensis. It exhibits a range of biological activities including anti-inflammatory, anti-tumor, immunomodulatory, and chemopreventive effects. Mechanistically, hirsutenone acts as an inhibitor of Proto-oncogene serine/threonine-protein kinase Akt1/2 by direct binding in an ATP-noncompetitive manner and suppresses downstream mTOR signaling. It also inhibits inflammatory mediators by suppressing Toll-like receptor 4 expression-mediated Nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kappaB) activation regulated via the ERK pathway. Hirsutenone has demonstrated protective effects on epithelial tight junctions through activation of Epidermal growth factor receptor/Akt and Extracellular signal-regulated kinase 1/2 pathways leading to increased heme oxygenase-1 (HO-1) expression. Preclinical studies suggest potential applications in cancer (notably prostate cancer), inflammatory skin diseases, atopic dermatitis, and inflammatory bowel disease.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on hirsutenone.